Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned

Critical Care Medicine

Volumn 29, Issue 7 SUPPL., 2001, Pages

  Reinhart, K ^a   Karzai, W ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Anti tumor necrosis factor therapy; Monoclonal antibodies; Sepsis; Tumor necrosis factor; Tumor necrosis factor receptor proteins

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MEDIATOR RELEASE; MEDICAL LITERATURE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL;

EID: 0034913364     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200107001-00037     Document Type: Conference Paper

References (41)

1. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis
2. Antiinflammatory therapies to treat sepsis and septic shock: A reassessment
3. Antibiotics versus cardiovascular support in a canine model of human septic shock
4. Sepsis and cytokines: Current status
5. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome
6. Plasma tumor necrosis factor and mortality in critically ill septic patients
7. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans
8. Detection of tumor necrosis factor after endotoxin administration
9. Tumor necrosis factor challenges in canines: Patterns of cardiovascular dysfunction
10. Endotoxin, tumor necrosis factor, and related mediators: New approaches to shock
11. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin
12. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
13. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: The CB0006 Sepsis Syndrome Study Group
14. CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock; CDP571 Sepsis Study Group
15. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial
16. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor α in patients with sepsis
17. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
18. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
19. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study
20. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial
21. Pattern of soluble TNF receptors I and II in sepsis
22. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: The Soluble TNF Receptor Sepsis Study Group
23. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock
24. Impact of immunomodulating therapy on morbidity in patients with severe sepsis
25. Biological effect of afelimomab on serum IL-6 and TNF concentrations
26. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III study
27. A short-term study of chimeric monoclonal antibody cA2 for the maintenance of of remission in Crohns disease
28. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor α
29. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation
30. Tumor necrosis factor and endotoxin can cause neutrophil activation through separate pathways
31. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection
32. Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice
33. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis
34. Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis
35. Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats
36. G-CSF during E. coli versus S. aureus pneumonia in rats has fundamentally different and opposite effects
37. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats
38. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: An overview
39. Sensitivity and specificity of various markers of inflammation for the prediction of tumour necrosis factor-alpha and interleukin-6 in patients with sepsis
40. Interferon γ-1b in the treatment of compensatory anti-inflammatory response syndrome; A new approach: Proof of principle
41. Procalcitonin: A new indicator of the systemic response to severe infections